A 27-year-old at Norwood 3 is starting a hair loss treatment journey using finasteride, dutasteride, minoxidil, biotin, scalp massages, and ketoconazole shampoo. The focus is on reducing DHT and stimulating growth, with finasteride emphasized as the key long-term solution.
A 19-year-old experienced significantly low testosterone levels after one month of taking finasteride. Suggestions included checking test units, retesting, and exploring other potential causes.
The user noticed increased hair loss over the past three years and is seeking advice. A suggestion was made to consult a dermatologist or trichologist and consider blood tests, particularly for vitamin D levels, to address potential androgenetic alopecia (AGA).
The user shared their 6-month hair loss progress, detailing a change in routine from using Minoxidil foam, topical Dutasteride, and topical Finasteride to using Minoxidil, oral Finasteride, derma rolling, and Keto shampoo. They seek suggestions for further improvements.
The user is concerned about high DHT levels despite using finasteride and dutasteride for hair loss, suggesting these treatments may not be effective. They plan to consult an endocrinologist and consider other antiandrogens, acknowledging potential side effects.
The conversation discusses the importance of scalp biopsies for diagnosing hair loss conditions like DUPA and Retrograde, which may not be just AGA. It emphasizes that treatments like finasteride and dutasteride may not work if the condition is autoimmune.
The user started shedding hair after beginning testosterone replacement therapy (TRT) despite using dutasteride and minoxidil, and added RU58841 to address the shedding. They reduced their TRT dose and hope RU58841 will stop the shedding quickly.
The user experienced significant hair regrowth using topical finasteride and minoxidil but faced a prolonged shedding phase, leading them to increase the finasteride dose and add oral dutasteride. Despite concerns about shedding, they remain hopeful for regrowth and are supplementing with Vitamin D.
GT20029 showed significant hair growth and safety in phase II trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.